TABLE 2.
Comparison of Hamilton depression rating score and serum biomarkers in the two study groups.
| Character | Group (1) control group (n = 27) | Group (2) atorvastatin group (n = 26) | b p-value | ||||
|---|---|---|---|---|---|---|---|
| Before treatment | After treatment | a p-value | Before treatment | After treatment | a p-value | After treatment | |
| HDRS (ITT) | 25.33 ± 1.90 | 16.67 ± 3.754 | >0.0001 (t = 10.20, df = 29) | 25.43 ± 1.794 | 14.30 ± 5.08 | >0.0001 (t = 12.95, df = 29) | 0.04 (t = 2.052, df = 58) |
| HDRS (PPA) | 25.33 ± 1.90 | 15.78 ± 2.722 | >0.0001 (t = 15.07, df = 26) | 25.43 ± 1.794 | 12.50 ± 2.025 | >0.0001 (t = 40.97, df = 25) | 0.0002 (t = 4.959, df = 51) |
| IL-6 (pg/mL) | 191.4 ± 19.1 | 186.1 ± 20.34 | 0.016 (t = 2.568, df = 26) | 193.3 ± 17.89 | 173.5 ± 17.14 | 0.0006 (t = 3.849, df = 25) | 0.018 (t = 2.429, df = 51) |
| STAT-3 (pg/mL) | 279 ± 11.44 | 222.4 ± 7.623 | >0.0001 (t = 53.79, df = 26) | 277.2 ± 10.57 | 179.4 ± 36.19 | >0.0001 (t = 12.55, df = 25) | >0.0001 (t = 6.042, df = 51) |
| NLRP-3 (pg/mL) | 164.3 ± 12.43 | 156.6 ± 12.19 | 0.002 | 162.7 ± 11.71 (t = 3.412, df = 26) | 147.0 ± 10.84 | >0.0001 (t = 6.215, df = 25) | 0.004 (t = 2.998, df = 51) |
| AMPK (ng/mL) | 65.81 ± 5.135 | 146.1 ± 15.06 | >0.0001 (t = 28.26, df = 26) | 64.29 ± 3.255 | 157.1 ± 15.85 | >0.0001 (t = 31.27, df = 25) | 0.015 (t = 2.574, df = 51) |
Data are expressed as mean ± SD, Significance at (p < 0.05). per protocol analysis (PPA), intension to treat analysis (ITT), Interleukin-6 (IL-6), adenosine monophosphate activated protein kinase (AMPK), nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3 (NLRP-3), signal transducer and activator of transcription factor-3 (STAT-3), Hamilton Depression Rating Scale (HDRS), (a) within group comparison, (b) between group comparison.